Clinical Trial Detail

NCT ID NCT01833143
Title Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan-Kettering Cancer Center|Millennium Pharmaceuticals, Inc.
Indications

lung non-small cell carcinoma

Therapies

Bortezomib

Age Groups: adult

No variant requirements are available.